Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* AnICD-10 schizophrenia diagnosis F20.0-F20.9.~* Contraception.~* A negative pregnancy test for women.~* No known allergy to any of the substances in the study medication~* Baseline QTc \< 450 milliseconds for men and \< 470 milliseconds for women~* S-potassium and s-magnesium within normal reference range.~* Suboptimally treated on current antipsychotic medication~* Stable dosage of antidepressants and mood stabilizers one month before the inclusion~* Signed informed consent and power of attorney~Exclusion Criteria:~* Withdrawal of consent~* QTc prolongation \>500 milliseconds during the study~* Patients with known clinical important cardiovascular disease~* Significant substance abuse~* Earlier partial or non-response in treatment or intolerability to sertindole or olanzapine.~* Calgary Depression Scale score ≥ 7~* Treatment that interferes with the metabolism of sertindole or olanzapine,~* Oxazepam, zopiclone or zolpidem treatment the last 48 hours before cognitive testing~* Prescription of not-allowed medication, or a change in dosage of antidepressant, or mood stabilizers in the study period~* Treatment with an anticholinergic after the first three weeks of the study~* Somatic illness, as judged by investigator, interfering with cognition~* Known risk of narrow angle glaucoma~* Treatment with electroconvulsive therapy (ECT) the last three months before inclusion, or treatment with ECT in the study period~* Treatment with clozapine or depot antipsychotics before inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Sertindole (Type: ACTIVE_COMPARATOR): Sertindole 16-24 mg
- Olanzapine (Type: ACTIVE_COMPARATOR): Olanzapine 10-20 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).